Picture Berlin Partner Voices Martin Rahmel TU Berlin GreenChem 650x100px
Document › Details

H. Lundbeck A/S. (4/8/22). "Press Release: Joerg Hornstein to Join Lundbeck as Chief Financial Officer and Head of Corporate Functions". Valby.

Organisations Organisation H. Lundbeck A/S
  Group Lundbeck (Group)
  Organisation 2 AC Immune S.A. (Nasdaq: ACIU)
Products Product CNS drug (neurological drug)
  Product 2 foods & beverages
Persons Person Hornstein, Jörg (Lundbeck 202209– CFO before AC Immune + Theo Müller Group + Merck KGaA)
  Person 2 Dunsire, Deborah (Lundbeck 201809– CEO before XTuit Pharma + Forum/EnVivo Pharma + Millennium/Takeda)

H. Lundbeck A/S (Lundbeck) is pleased to announce Joerg Hornstein is appointed as Chief Financial Officer (CFO) and member of Lundbeck’s Executive Management. He will assume the role no later than September 1, 2022, and he will be registered with the Danish Business Authority.

Joerg is an action-oriented, change-driven leader with a strong track record in integrating, restructuring, scaling up, and improving business performance and productivity in pharmaceutical, biotech and fast-moving consumer goods (FMCG) industries. He has proven experience in executive management roles and as a principal financial advisor to Boards of Directors.

Joerg will join Lundbeck from AC Immune, a clinical-stage biopharmaceutical company specialized in precision medicine to diagnose, treat and prevent neurodegenerative diseases, headquartered in Lausanne, Switzerland, where he currently serves as Executive Vice President and Chief Financial Officer.

“Following a thorough internal and external search, we are delighted to welcome Joerg to Lundbeck. He brings extensive experience in delivering results and creating value across increasingly complex financial roles in Merck KGaA, Unternehmensgruppe Theo Mueller, and most recently as CFO of AC Immune. Joerg has a strong mix of understanding of neuroscience and pharma, exceptional operational experience across multiple functions and countries and demonstrated ability to lead through business transformations. The insights he has gained by leading across cultures and through periods of significant change, will be valuable in ensuring Lundbeck continues to be well positioned for sustainable, long-term value creation in the years ahead,” said Deborah Dunsire, CEO of Lundbeck.

Joerg has been with AC Immune as Executive Vice President and Chief Financial Officer since 2017, where he oversaw Finance and various corporate functions. Over the years, he led a financial transformation of the company’s operations leading to a strengthened financial and investor position. He also implemented state of the art systems and processes across all corporate functions and a new portfolio investment approach. The company is listed on NASDAQ stock exchange in the United States.

Prior to AC Immune, he served as Senior Vice President and Head of Group Controlling for Unternehmensgruppe Theo Mueller, a consumer products company with operations across the entire value chain, with annual revenue of approximately 7 billion Euros. In this role Joerg transformed the financial profile of the business during periods of major acquisitions and significant organic growth.

Joerg started his career with Merck KGaA where he spent 12 years in financial roles of increasing responsibility across different businesses, including roles at the Headquarters in Germany, as well as in Indonesia, China and the USA. He has lived in six countries and is a German national.

Lundbeck contacts

Palle Holm Olesen
Vice President, Investor Relations
+45 30 83 24 26

Thomas Mikkel Mortensen
Media Relations Lead, Corp. Communication
+45 30 83 30 24

About H. Lundbeck A/S

Lundbeck is a global pharmaceutical company specialized in brain diseases. For more than 70 years, we have been at the forefront of neuroscience research. We are tirelessly dedicated to restoring brain health, so every person can be their best. We are committed to fighting stigma and discrimination against people living with brain diseases and advocating for broader social acceptance of people with brain health conditions. Our research programs tackle some of the most complex challenges in neuroscience, and our pipeline is focused on bringing forward transformative treatments for brain diseases for which there are few, if any therapeutic options.

For additional information, we encourage you to visit our corporate site and connect with us on Instagram (h_lundbeck), Twitter at @Lundbeck and via LinkedIn.

Safe Harbor/Forward-Looking Statements

This corporate release contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions, product approvals and financial performance. Forward looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words like "believe", "anticipate", "expect", "estimate", "intend", "plan", "project", "will be", "will continue", "will result", "could", "may", "might", or any variations of such words or other words with similar meanings. All statements other than statements of historical facts included in this presentation, including, without limitation, those regarding our financial position, business strategy, plans and objectives of management for future operations (including development plans and objectives relating to our products), are forward looking statements.

Such forward looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements. Factors that may affect future results include, among others, interest rate and currency exchange rate fluctuations, delay or failure of development projects, production or distribution problems, unexpected contract breaches or terminations, government-mandated or market-driven price decreases for Lundbeck's products, introduction of competing products, Lundbeck's ability to successfully market both new and existing products, exposure to product liability and other lawsuits, changes in reimbursement rules and governmental laws and related interpretation thereof, and unexpected growth in costs and expenses.

The forward-looking statements in this document and oral presentations made on behalf of Lundbeck speak only as at the date of this presentation. Lundbeck does not undertake any obligation to update or revise forward-looking statements in this presentation or oral presentations made on behalf of Lundbeck, nor to confirm such statements to reflect subsequent events or circumstances after the date of the presentation or in relation to actual results, unless otherwise required by applicable law or applicable stock exchange regulations.

H. Lundbeck A/S
Ottiliavej 9, 2500 Valby, Denmark
+45 3630 1311

Record changed: 2023-06-05


Picture EBD Group World of Partnering Opportunities 650x200px

More documents for Lundbeck (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Berlin Partner Voices Martin Rahmel TU Berlin GreenChem 650x300px

» top